Login to Your Account



Other News To Note


Wednesday, April 13, 2011
Ensemble Therapeutics Corp., of Cambridge, Mass., triggered a milestone payment from partner Bristol-Myers Squibb Co., of Princeton, N.J., by developing an Ensemblin-based therapeutic against one of the targets in their collaboration. Achievement of the milestone was based on specific criteria of the drug, including potency, selectivity and pharmacokinetics. That drug target program will now transition to BMS for development.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription